Cancer treatment has evolved with CAR T-cell therapy, where patients’ immune cells are engineered to target cancer. Developed by UCL’s Professor Waseem Qasim, it has shown promise in reversing aggressive blood cancers, with a patient cancer-free for three years. However, it faces challenges in treating solid tumors and manufacturing costs.